Moderna and Merck Report mRNA Cancer Vaccine Reduces Death and Recurrence by 42%
Source Summary
Moderna and Merck announced top-line results from their mRNA cancer vaccine trial, showing a 42% reduction in death and recurrence rates. The companies had previously reported that the trial met its primary endpoint. The vaccine represents a collaborative development between the two pharmaceutical firms.
Why it matters
A 42% reduction in cancer death and recurrence rates represents a significant clinical advance in mRNA vaccine technology applied to oncology treatment.
